Management of fever in neutropenic patients with different risks of complications

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 1, 2004, Pages

  Klastersky, Jean ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; GLYCOPEPTIDE; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; EMPIRICISM; FEBRILE NEUTROPENIA; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRANULOCYTOPENIA; HIGH RISK POPULATION; HOME CARE; HOSPITAL ADMISSION; HUMAN; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG THERAPY, COMBINATION; FEVER; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; RISK ASSESSMENT;

EID: 3242766680     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383050     Document Type: Conference Paper

References (22)

1. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996; 40:1108-15.
2. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247-59.
3. Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341:312-8.
4. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341:305-11.
5. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10:316-22.
6. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-51.
7. McCabe WR, Jackson GG. Gram negative bacteremia. I. Etiology and ecology. Arch Intern Med 1962; 110:847-50.
8. McCabe WR, Jackson GG. Gram negative bacteremia. II. Clinical, laboratory, and therapeutic observations. Arch Intern Med 1962; 110:865.
9. The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Eng J Med 1987; 317:1692-8.
10. Giamarellou H, Bassaris HP, Petrikkos G, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother 2000; 44:3264-71.
11. Agaoglu L, Devecioglu O, Anak S, et al. Cost-effectiveness of cefepime plus netilmicine or ceftazidime plus amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 2001; 13:281-7.
12. Duzova A, Kutluk T, Kanra G, et al. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr 2001; 43:105-9.
13. Cornely OA, Bethe U, Salzberger B, et al. Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever. Ann Hematol 2001; 80:103-8.
14. Ariffin H, Navaratman P, Mohamed M, et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infections in children with febrile neutropenia. Int J Infect Dis 2000; 4:21-5.
15. Klastersky J. La neutropénie febrile: l'antibiothérapie empirique de 1975 à 1997. Rev Med Brux 1997; 18:323-7.
16. Cordonnier C, Herbrecht R, Picu JL, et al. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis 1997; 24:41-51.
17. Bohme A, Shah PM, Stille W, Hoelzer P. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998; 3:324-30.
18. Jandula BM, Martino R, Gurgi M, Manteiga R, Sierra J. Treatment of febrile neutropenia with cefepime monotherapy. Chemotherapy 2001; 47:226-31.
19. Kebudi R, Gorgun O, Ayan I, et al. Randomized comparison of Cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol 2001; 36:434-41.
20. Mustafa MM, Carlson L, Tkaczewski I, McCracken GH Jr, Buchanan GR. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2001; 20:362-9.
21. Vancomycin added to empirical combination therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis 1991; 163:951-8.
22. Corey L, Boeckh M. Persistent fever in patients with neutropenia. N Engl J Med 2002; 346:222-4.